Pervasis Therapeutics Secures $9,750,000 New Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=78a8bb6d-7436-4b20-a614-b0c9b8446bd5&Preview=1 -
Date
1/15/2008 -
Company Name
Pervasis Therapeutics -
Mailing Address
One Kendall Square, Building 600 Cambridge, MA 02139 -
Company Description
Pervasis Therapeutics is focused on creating biologically active vascular technologies to treat significant unmet needs in cardiovascular disease. -
Website
http://www.pervasistx.com -
Transaction Type
Venture Equity -
Transaction Amount
$9,750,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
The new investment will support further development of Pervasis’ innovative Vascugel® blood vessel repair therapeutic, presently in two Phase II clinical trials, as well as continuing research into expanding the product’s projected uses into additional vascular and non-vascular applications, including cardiovascular and other indications. -
M&A Terms
-
Venture Investor
Flagship Ventures -
Venture Investor
Polaris Venture Partners -
Venture Investor
Highland Capital Partners
